检索结果-南通市图书馆

Inhibition of FLT3:A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia

Engineering 2021年第10期7卷 1354-1368页

作者： meira yisraeli salman Jacob M.Rowe Nir Weigert Department of Hematology Shaare Zedek Medical CenterJerusalem 9103102Israel Department of Hematology and Bone Marrow Transplantation Rambam Medical CenterHaifa 3109601Israel Technion—Israel Institute of Technology Haifa 3200003Israel

Modern therapy of acute myeloid leukemia(AML)began in 1973 with the first report of the successful combination of daunorubicin and cytarabine,which led to complete remission in approximately 45%of *** AML diagnosis was dependent on morphology,aided initially only by *** acute lymphoblastic leukemia(ALL),immunophenotyping offered little in the diagnosis of AML,at least during the 1970s and *** advent of reliable cytogenetics changed the entire prognostic outlook of *** karyotypic analysis,different groups of AML could be classified and stratified for various *** mutational profiling was a major advance in further categorizing AML patients,aided by the immunophenotypic identification of antigenic markers on the *** these advances were occurring as the understanding of the importance of the tumor burden—known as minimal residual disease(MRD)—became crucial for the management of AML *** efficacy of MRD has rapidly progressed in the past decade,from a specificity of 103 with immunophenotyping to 104 with polymerase chain reaction(PCR),which is only appropriate for some patients with AML,and finally to 105 or even 106 cells with the extraordinary sensitivity of next-generation sequencing(NGS).All of these advances have promoted the concept of personalized medicine,which has led to the advent of targeted agents that can accurately be used for specific diagnostic *** can be predicted and measured *** targeted agents have now become a cornerstone in the management of AML,increasing effi-cacy and dramatically reducing *** focus of this review is on one of the most well-studied targeted agents in AML:the FMS-like tyrosine kinase 3(FLT3)inhibitors,which have impacted the prognostication and therapeutics of *** review selectively discusses the FLT3 inhibitors in detail,as a model for the other burgeoning targeted agents that have already been approved,as well as tho

关键词： AML Targeted therapy FLT3 inhibitors Midostaurin Gilteritinib Quizartinib Sorafenib

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：